Researchers evaluated the ability of a polygenic risk score constructed from a genome-wide association study of rheumatoid arthritis susceptibility to predict radiographic progression, which is ...

Nonradiographic axial spondyloarthritis (nr-axSpA) progressed to radiographic disease (r-axSpA) in approximately 16% of adults with new-onset disease within a 5-year period, and progression was ...

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar. Both secukinumab ...

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease that predominantly affects the axial skeleton. 1 axSpA is an umbrella term that comprises the whole spectrum ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

Oral baricitinib is linked to lower levels of 5-year radiographic progression than first-line conventional, synthetic disease-modifying antirheumatic drugs or placebo in rheumatoid arthritis, ...

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying ...

MILAN, Italy — Secukinumab (Cosentyx) and biosimilar adalimumab-adaz (Hyrimoz) injection proved to have similar efficacy for limiting spinal radiographic progression over a 2-year period in patients ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not ...

Researchers from Tokyo Medical and Dental University (TMDU) investigate polygenic risk score as a predictor of radiographic progression in rheumatoid arthritis Watch ...